Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.5.1911

SELDI-TOF MS Combined with Magnetic Beads for Detecting Serum Protein Biomarkers and Establishment of a Boosting Decision Tree Model for Diagnosis of Pancreatic Cancer  

Qian, Jing-Yi (Medical Services Section, Taizhou Municipal Hospital)
Mou, Si-Hua (Department of Clinical Laboratory, Taizhou Municipal Hospital)
Liu, Chi-Bo (Department of Clinical Laboratory, Taizhou Municipal Hospital)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.5, 2012 , pp. 1911-1915 More about this Journal
Abstract
Aim: New technologies for the early detection of pancreatic cancer (PC) are urgently needed. The aim of the present study was to screen for the potential protein biomarkers in serum using proteomic fingerprint technology. Methods: Magnetic beads combined with surface-enhanced laser desorption/ionization (SELDI) TOF MS were used to profile and compare the protein spectra of serum samples from 85 patients with pancreatic cancer, 50 patients with acute-on-chronic pancreatitis and 98 healthy blood donors. Proteomic patterns associated with pancreatic cancer were identified with Biomarker Patterns Software. Results: A total of 37 differential m/z peaks were identified that were related to PC (P < 0.01). A tree model of biomarkers was constructed with the software based on the three biomarkers (7762 Da, 8560 Da, 11654 Da), this showing excellent separation between pancreatic cancer and non-cancer., with a sensitivity of 93.3% and a specificity of 95.6%. Blind test data showed a sensitivity of 88% and a specificity of 91.4%. Conclusions: The results suggested that serum biomarkers for pancreatic cancer can be detected using SELDI-TOF-MS combined with magnetic beads. Application of combined biomarkers may provide a powerful and reliable diagnostic method for pancreatic cancer with a high sensitivity and specificity.
Keywords
Pancreatic cancer; biomarker; protein; SELDI-TOF-MS; diagnosis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Adam BL, Qu Y, Davis JW, et al (2002). Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res, 62, 3609-14.
2 DiMagno EP, Reber HA, Tempero MA (1999). Epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology, 117, 1463-84.   DOI   ScienceOn
3 Ebert MP, Meuer J, Wiemer JC, et al (2004). Identification of gastric cancer patients by serum protein profiling. J Proteome Res, 3, 1261-6.   DOI
4 Guo R, Pan C, Shen J, et al (2011). New serum biomarkers for detection of esophageal carcinoma using Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J Cancer Res Clin Oncol, 137, 513-9.   DOI
5 Hortin GL (2006). The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem, 52, 1223-37.   DOI
6 Liu C, Pan C, Shen J, et al (2011). MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of colorectal cancer. Int J Med Sci, 8, 39-47.   DOI
7 Liu C, Wang H, Pan C, et al (2010). Serum protein fingerprint of patients with gastric cancer by SELDI technology. African J Biotechnol, 9, 2298-304.
8 Kim JE, Lee KT, Lee JK, et al (2004). Clinical usefulness of Carbohydrate antigen 199 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol, 19, 182-6.   DOI
9 Kim EJ, Simeone DM, (2011). Advances in pancreatic cancer. Curr Opin Gastroenterol, 27, 460-6.   DOI
10 Liang Y, Fang M, Li J, et al (2006). Serum proteomic patterns for gastric lesions as revealed by SELDI mass spectrometry. Exp Mol Pathol, 81, 176-80.   DOI
11 Li D, Xie K, Wolff R, et al (2004). Pancreatic cancer. Lancet, 363, 1049-57.   DOI   ScienceOn
12 Liotta LA, Ferrari M, Petricoin E (2003). Clinical proteomics: written in blood. Nature, 425, 905.   DOI
13 Liu CB, Liang Y, Pan CQ, et al (2009). Proteome study of differential protein expression in HBV-related primary hepatic carcinoma. Chem J Chinese Universities, 30, 1763-6.
14 Liu C, Shen J, Pan C, et al (2010). MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of hepatocellular carcinoma. Am J Clin Pathol, 134, 235-41   DOI
15 Schwegler EE, Cazares L, Steel LF, et al (2005). SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology, 41, 634-42.   DOI
16 Ward DG, Cheng Y, N'Kontchou G, et al (2006). Preclinical and post-treatment changes in the HCC-associated serum proteome. Br J Cancer, 95, 1379-83.   DOI
17 Semmes OJ, Feng Z, Adam BL, et al (2005). Evaluation of serum protein profiling by surface-enhanced laser desorption/ ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem, 51, 102-12.
18 Singh S, Tang SJ, Sreenarasimhaiah J, et al (2011). The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig Dis Sci, 56, 2491-6.   DOI
19 Wagner M, Naik DN, Pothen A, et al (2004). Computational protein biomarker prediction: a case study for prostate cancer. BMC Bioinformatics, 5, 26.   DOI
20 Ward DG, Suggett N, Cheng Y, et al (2006). Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer, 94, 1898-905.   DOI